@article{Abdulmalik_Darwish_Muralidharan-Chari_Taleb_Mousa_2022, place={Pavia, Italy}, title={Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling <i>in vitro</i>, and prolongs survival of sickle cell mice under hypoxia}, volume={107}, url={https://haematologica.org/article/view/haematol.2020.272393}, DOI={10.3324/haematol.2020.272393}, abstractNote={<p>Sickle cell disease (SCD) is an autosomal recessive genetic disease caused by a single point mutation, resulting in abnormal sickle hemoglobin (HbS). During hypoxia or dehydration, HbS polymerizes to form insoluble aggregates and induces sickling of red blood cells, which increases the adhesiveness of the cells, thereby altering the rheological properties of the blood, and triggers inflammatory responses, leading to hemolysis and vaso-occlusive crises. Unfractionated heparin and low-molecular weight heparins have been suggested as treatments to relieve coagulation complications in SCD. However, they are associated with bleeding complications after repeated dosing. An alternative sulfated non-anticoagulant heparin derivative (S-NACH) was previously reported to have no to low systemic anticoagulant activity and no bleeding side effects, and it interfered with P-selectin-dependent binding of sickle cells to endothelial cells, with concomitant decrease in the levels of adhesion biomarkers in SCD mice. S-NACH has been further engineered and structurally enhanced to bind with and modify HbS to inhibit sickling directly, thus employing a multimodal approach. Here, we show that S-NACH can: (i) directly engage in Schiff-base reactions with HbS to decrease red blood cell sickling under both normoxia and hypoxia &lt;i&gt;in vitro&lt;/i&gt;, (ii) prolong the survival of SCD mice under hypoxia, and (iii) regulate the altered steady state levels of pro- and anti-inflammatory cytokines. Thus, our proof-of-concept, in vitro and in vivo preclinical studies demonstrate that the multimodal S-NACH is a highly promising candidate for development into an improved and optimized alternative to low-molecular weight heparins for the treatment of patients with SCD.</p&gt;}, number={2}, journal={Haematologica}, author={Abdulmalik, Osheiza and Darwish, Noureldien H.E. and Muralidharan-Chari, Vandhana and Taleb, Maii Abu and Mousa, Shaker A.}, year={2022}, month={Feb.}, pages={532-540} }